ROCHE-AVF2192g



A phase II, multicenter, double-blind, randomized, active-controlled clinical trial to evaluate the efficacy and safety of rhumab vegf (bevacizumab), a recombinant humanized monoclonal antibody to vascular endothelial growth factor, in combination with 5-fluorouracil and leucovorin chemotherapy in subjects with metastatic colorectal cancer who are not optimal candidates for first-line cpt-11
bevacizumab
AVF2192g
NCT00109226
metastatic colorectal cancer
Phase 2
 
January 2014